ArticleAdvanced healthcare materials2025
Biphasic Granular Bioinks for Biofabrication of High Cell Density Constructs for Dermal Regeneration.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enzyme responsive antimicrobial hyaluronan-nanocellulose hybrid wound dressings for the treatment of infected wounds.Bioactive materials · 2026Article
- Intelligent design and application of molecular recognition hydrogels in tissue engineering.Materials today. Bio · 2026Review
- Biphasic Granular Bioinks for Biofabrication of High Cell Density Constructs for Dermal Regeneration.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Chronic wounds and severe skin injuries pose significant clinical challenges, as existing treatments like cultured epidermal autografts and tissue engineering strategies fail to regenerate functional dermal tissue effectively. These methods often result in scarring due to poor tissue integration, low cell density, and limited extracellular matrix (ECM) production. Conventional skin tissue engineering relies on time-intensive cell expansion, producing constructs that lack the complexity of native dermal structures. Here, a bioprintable biphasic granular hydrogel bioink (µInk) based on cell-laden porous gelatin microcarriers (PGMs) is presented, enabling fabrication of ultra-high cell density constructs that promote ECM production for dermal regeneration in vitro and in vivo. Primary human dermal fibroblasts are cultured and expanded on PGMs in a bioreactor prior µInk formulation. The cell-laden PGMs are cross-linked via copper-free click chemistry, creating a shear-thinning granular bioink. The µInk is 3D bioprinted into structurally stable constructs with high cell viability. In vivo, the bioprinted constructs supported neovascularization, hydrogel remodeling, and tissue integration over 28 days. Cells maintained their tissue-specific phenotype, proliferated, and produced dermal ECM post-transplantation. The µInk offers a promising approach to generating high cell-density constructs for scar-free wound healing and for advancing complex tissue reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.